Godavari Biorefineries Limited announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment.

The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies.  The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.

"This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation."

Godavari Biorefineries’ clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world’s most urgent health challenges.

This development highlights GBL’s growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks.